Sichuan Kelun Pharmaceutical Co., Ltd. Class A
002422
Pozycja w akcjach
#2010
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and... Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injections. In addition, the company engages in investment; import and export; enterprise management; logistics and transportation; business services; agricultural non-staple food processing; production and sale of pharmaceutical intermediates; research and development of bio-based materials technology; Internet and related services; crop planting; professional technical; biotechnology extension; socio-economic consultation; technology promotion; medical research and testing exhibition; general cargo road transport; ecological protection and environmental management; and wholesale and retail. It exports its products to Japan. The company was formerly known as Sichuan Kelun Pharmaceutical Factory Co., Ltd and changed its name to Sichuan Kelun Pharmaceutical Co., Ltd. in August 2003. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Industry Group CO., LTD.
Cena akcji
$6.40
Kapitalizacja rynkowa
$10.19B
Zmiana (1 dzień)
-0.77%
Zmiana (1 rok)
27.14%
Kraj
CN
Handel Sichuan Kelun Pharmaceutical Co., Ltd. Class A (002422)
Kategoria
Healthcare
Marża operacyjna dla Sichuan Kelun Pharmaceutical Co., Ltd. Class A (002422)
Marża operacyjna na dzień October 2026 TTM: 8.12%
Według najnowszych raportów finansowych i ceny akcji Sichuan Kelun Pharmaceutical Co., Ltd. Class A, bieżąca marża operacyjna (TTM) wynosi 8.12%. Na koniec 2024 wynosiła 20.29%.
Historia marży operacyjnej dla Sichuan Kelun Pharmaceutical Co., Ltd. Class A od 2007 do 2026
Marża operacyjna na koniec każdego roku
| Rok | Marża operacyjna | Zmień |
|---|---|---|
| 2026 (TTM) | 8.12% | -25.98% |
| 2025 | 10.97% | -45.93% |
| 2024 | 20.29% | 19.14% |
| 2023 | 17.03% | 47.70% |
| 2022 | 11.53% | 50.92% |
| 2021 | 7.64% | 24.63% |
| 2020 | 6.13% | -15.33% |
| 2019 | 7.24% | -12.67% |
| 2018 | 8.29% | -18.08% |
| 2017 | 10.12% | 32.63% |
| 2016 | 7.63% | 3.25% |
| 2015 | 7.39% | -45.54% |
| 2014 | 13.57% | -19.27% |
| 2013 | 16.81% | -19.99% |
| 2012 | 21.01% | 1.99% |
| 2011 | 20.60% | 9.93% |
| 2010 | 18.74% | 20.36% |
| 2009 | 15.57% | 15.59% |
| 2008 | 13.47% | 10.86% |
| 2007 | 12.15% | 0.00% |
Marża operacyjna dla podobnych firm lub konkurentów
| Firma | Marża operacyjna | Różnica w marży operacyjnej | Kraj |
|---|---|---|---|
| 38.59% | -95.25% |
US
|
|
| -149.01% | -118.35% |
US
|
|
| 25.57% | -96.85% |
AU
|
|
| 31.23% | -96.15% |
BE
|
|
| 28.81% | -96.45% |
NL
|
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.